• In late June 2026, Addus HomeCare Corporation (NasdaqGS: ADUS) was removed from several Russell Growth indices, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Growth benchmarks, following the annual index reconstitution.
• This broad index removal matters because it can alter demand from index-tracking funds and active managers, potentially reshaping liquidity and the shareholder base for Addus HomeCare.
• Next, we’ll examine how Addus HomeCare’s broad removal from Russell Growth indices may influence its previously outlined investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Addus HomeCare Investment Narrative Recap

To own Addus HomeCare, you have to believe in the long term demand for home and community based care and the company’s ability to manage reimbursement and labor pressures. The broad removal from Russell Growth indices is a market structure event that may affect trading liquidity, but it does not directly change the core near term catalyst around state reimbursement trends or the central risk from Medicare and Medicaid policy uncertainty.

The most relevant recent update here is the Q1 2026 earnings release, which showed continued profitability growth with net income of US$25.07 million and diluted EPS of US$1.36. For investors, that report helps frame how Addus is executing on its personal care and acquisition driven growth story just as index related flows and potential shareholder turnover may start to look different after the Russell changes.

Yet, while index removal might seem technical, it could still matter for those policy and reimbursement risks investors should be aware of...

Addus HomeCare's narrative projects $1.7 billion revenue and $142.2 million earnings by 2029.

Uncover how Addus HomeCare's forecasts yield a $132.69 fair value, a 21% upside to its current price.

Exploring Other Perspectives

The lowest estimating analysts paint a more cautious picture, even before the index removals, with revenue only reaching about US$1.6 billion and earnings US$124.8 million by 2029, which shows how differently you and others might weigh government funding risks and possible shifts in investor demand after the Russell changes.

Explore 4 other fair value estimates on Addus HomeCare - why the stock might be worth just $111.80!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Addus HomeCare research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Addus HomeCare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Addus HomeCare's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.